The ERK mitogen-activated protein kinase signaling network: the final frontier in RAS signal transduction

Area of Science:

• Molecular Biology
• Cellular Signaling
• Oncology

Background:

• The RAF-MEK-ERK mitogen-activated protein kinase (MAPK) cascade is frequently hyperactivated in human cancers and RASopathies.
• This pathway, a focus of pharmaceutical development, has over 30 inhibitors in clinical use or evaluation.
• Initially viewed as linear, the ERK-MAPK cascade is now recognized as a complex network with autoregulatory loops.

Purpose of the Study:

• To review recent advancements in understanding the ERK-MAPK signaling network.
• To highlight the complexity of cancer cell adaptation to ERK-MAPK pathway inhibition.
• To identify key unresolved questions for future research in ERK-MAPK signaling.

Main Methods:

• Literature review of studies on the RAF-MEK-ERK-MAPK pathway.
• Analysis of cancer cell adaptation mechanisms to pathway inhibitors.
• Synthesis of current knowledge and identification of research gaps.

Main Results:

• The ERK-MAPK cascade functions as a complex signaling network, not a simple linear pathway.
• Cancer cells demonstrate adaptive strategies to overcome inhibition of key ERK-MAPK nodes.
• Significant complexity in the ERK-MAPK network contributes to therapeutic resistance.

Conclusions:

• Despite extensive research and drug development, the ERK-MAPK network's complexity presents ongoing challenges.
• Further investigation into adaptive mechanisms is crucial for developing effective cancer therapies targeting this pathway.
• Unresolved issues in ERK-MAPK signaling necessitate continued research efforts.